Could the next boom in clinical trials involve the “Clinical Trials-on-a-Chip” wave? If a recently announced National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) grant is successful, this very well could transform how clinical trials are actually conducted. Currently, 85% of late-stage clinical trials of candidate drugs fail due to drug safety problems or ineffectiveness, despite the fact that preclinical tests showed well. To help improve the design and implementation of clinical trials, NIH has awarded 10 grants to support researchers’ efforts in using tiny, bioengineered models of human tissues and organ systems to study diseases and test drugs. One major goal of the funded projects is to develop ways to predict which patients are most likely to benefit from an investigational therapy prior to even starting a clinical trial, which are expensive and time-consuming.
The Funds & Funder
The awards total more than $6.9 million in the first year, and approximately $35.5 million over five years, pending available funds. They are administered through a new program, Clinical Trials on a Chip, which is led by NIH's National Center fo...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).